No Prescription |
 |
 | ||
|
Nizral |
|
| ||
No Prescription » Prescription Drugs 12 » Nizral Ketoconazole is used to treat skin infections such as athlete's foot jock itch ringworm and certain kinds of dandruff. This medication is also used to treat a skin condition known as pityriasis (tinea versicolor) a fungal infection that causes a lightening or darkening of the skin of the neck chest arms or legs. Ketoconazole is an azole antifungal that works by preventing the growth of fungus. Buy Nizral and other Prescription Drugs 12 products online at Medstore. Buy Online at Medstore - Click Here!
About Nizral: Product Type: Prescription Drugs 12 Nizral/Nizoral (Generic Ketoconazole) Nizral/Nizoral (Generic Ketoconazole) Generic Ketoconazole 200mg Generic Ketoconazole Nizral/Nizoral
View more Prescription Drugs 12 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
